Jeff Aronin is involved in building global biotech and other new healthcare companies. He is currently CEO of Paragon Biosciences. As an entrepreneur, he knows how to move forward, collaborate, and how to infect people with energetic enthusiasm. He knows how to find researchers who study new drugs and therapies for various genetic illnesses (Bloomberg). He has a background in complex science knowledge, rare disease, and developing new drugs. His teams create new medicines to market that improve the quality of life for many people. His goal is to help humanity overcome its problems with drugs that benefit all of humanity, as he is also a philanthropist.
He believes in the betterment of humanity, which he tries to surround himself with people who believe in the same. He has 13 novel drug approvals from the FDA, a higher success rate than that of comparable of his compatriots. Paragon Biosciences is a pharmaceutical investment firm. Aronin is chairman of other companies, such as Castle Creek Pharmaceuticals, Harmony Biosciences. In 2000-2009, Aronin was President and CEO of Ovation Pharmaceuticals, Inc., which was then acquired by Lundbeck, Inc. being sold for $900 million. He has many skills including strategic and business development (http://chicago.blueskyinnovation.com/vault/network/aronin-jeff/).
For these reasons, Aronin is the winner of the 2017 Weizmann Leadership Award also for his knowledge of finance and brand marketing. He has leadership experience as well as operations knowledge of day-to-day corporation management. An example of drugs that have been developed is one for, most often found in boys, and this drug is named Deflazacort, in the process of awaiting FDA approval. In addition to his work with pharmaceutical biotech companies, he is a board member of Discover Financial Services, the Museum of Science and Industry as well as the Economic Club of Chicago.